Company profile
Vaxart, Inc.
NASDAQ: VXRT · Healthcare · Biotechnology
#277 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
72BFH 79DQ 65GM 66SS 73
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, listing tenure · ↓ growth stability, filing timeliness
Methodology →Revenue TTM
$255.6M
Rev growth YoY (TTM)
+439.3%
Net income (FY)
$16.3M
Employees
65
as of 2026-08-14
Market cap
$135.5M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$237.3M$237.3M2025
Net income$16.3M$16.3M2025
Operating income$18.1M$18.1M2025
Total assets$186.1M$186.1M2025
Liabilities$98.3M$98.3M2025
Equity$87.8M$87.8M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Government Contract90%
Collaboration Revenue6%
License3%
Non Cash Royalty Revenue1%
By geography
Not disclosed.
The read
What is Vaxart, Inc.’s revenue?
Vaxart, Inc. booked $237.3M in FY2025 revenue, growing 727% year over year — faster than 95% of Healthcare companies we track, at a 6.9% net margin.
Peers · Healthcare
Keros Therapeutics, Inc.71BDefinitive Healthcare Corp.53DSTAAR Surgical Company67BOrthoPediatrics Corp.69BAkebia Therapeutics, Inc.66BAnaptysBio, Inc.75B+Neighbors
San Mateo →Key facts
CEOSteven Lo
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: VXRT
Employees65
IPO date1981-12-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.